Skip to Content

Clindamycin Phosphate Injection

Last Updated: May 7, 2020
Status: Current

Products Affected - Description
    • Cleocin injection, Pfizer, 150 mg/mL, 2 mL ADD-Vantage vial, 25 count, NDC 00009-6582-01
    • Cleocin injection, Pfizer, 150 mg/mL, 2 mL vial, 25 count, NDC 00009-0870-26
    • Cleocin injection, Pfizer, 150 mg/mL, 4 mL ADD-Vantage vial, 25 count, NDC 00009-3124-03
    • Cleocin injection, Pfizer, 150 mg/mL, 4 mL vial, 25 count, NDC 00009-0775-26
    • Cleocin injection, Pfizer, 150 mg/mL, 6 mL ADD-Vantage vial, 25 count, NDC 00009-3447-03
    • Cleocin injection, Pfizer, 150 mg/mL, 6 mL vial, 25 count, NDC 00009-0902-18
    • Clindamycin phosphate injection, Akorn, 300 mg/50 mL, in 5% dextrose premixed bottle, 1 count, NDC 17478-0120-50 - discontinued
    • Clindamycin phosphate injection, Akorn, 600 mg/50 mL, premixed bottle, 1 count, NDC 17478-0121-50 - discontinued
    • Clindamycin phosphate injection, Akorn, 900 mg/50 mL, premixed bottle, 1 count, NDC 17478-0122-50 - discontinued
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 2 mL ADD-Vantage vial, 25 count, NDC 72611-0762-25 - discontinued
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 4 mL ADD-Vantage vial, 25 count, NDC 72611-0767-25 - discontinued
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 6 mL ADD-Vantage vial, 25 count, NDC 72611-0769-25 - discontinued
    • Clindamycin phosphate injection, Baxter, 300 mg/50 mL, in 0.9% sodium chloride premixed container, 24 count, NDC 00338-9545-24
    • Clindamycin phosphate injection, Baxter, 300 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00338-3410-24
    • Clindamycin phosphate injection, Baxter, 600 mg/50 mL, in 0.9% sodium chloride premixed container, 24 count, NDC 00338-9549-24
    • Clindamycin phosphate injection, Baxter, 600 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00338-3612-24
    • Clindamycin phosphate injection, Baxter, 900 mg/50 mL, in 0.9% sodium chloride premixed container, 24 count, NDC 00338-9553-24
    • Clindamycin phosphate injection, Baxter, 900 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00338-3814-24
    • Clindamycin phosphate injection, Sagent, 150 mg/mL, 2 mL vial, 25 count, NDC 25021-0115-02
    • Clindamycin phosphate injection, Sagent, 150 mg/mL, 4 mL vial, 25 count, NDC 25021-0115-04
    • Clindamycin phosphate injection, Sagent, 150 mg/mL, 6 mL vial, 25 count, NDC 25021-0115-06
Reason for the Shortage
    • Alvogen injectable generic products including clindamycin are being marketed under the brand, Almaject Inc., as of October 1, 2019. The NDC numbers for these products have changed.
    • Akorn discontinued clindamycin injection in early 2020.
    • Baxter has clindamycin injection on shortage due to manufacturing delays.
    • Fresenius Kabi did not provide a reason for the shortage.
    • Pfizer did not provide a reason for the shortages. Pfizer discontinued Cleocin premixed bags in 2018.
    • Sagent did not provide a reason for the shortage.
    • Sandoz did not provide a reason for the shortage.
Available Products
    • Cleocin injection, Pfizer, 150 mg/mL, 60 mL bulk vial, 5 count, NDC 00009-0728-09
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 2 mL vial, 25 count, NDC 72611-0634-25
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 4 mL vial, 25 count, NDC 72611-0639-25
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 6 mL vial, 25 count, NDC 72611-0642-25
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 60 mL bulk vial, 1 count, NDC 72611-0645-55
    • Clindamycin phosphate injection, Fresenius Kabi, 150 mg/mL, 2 mL vial, 25 count, NDC 63323-0282-02
    • Clindamycin phosphate injection, Fresenius Kabi, 150 mg/mL, 4 mL vial, 25 count, NDC 63323-0282-04
    • Clindamycin phosphate injection, Fresenius Kabi, 150 mg/mL, 6 mL vial, 25 count, NDC 63323-0282-06
    • Clindamycin phosphate injection, Fresenius Kabi, 150 mg/mL, 60 mL vial, 1 count, NDC 63323-0282-60
    • Clindamycin phosphate injection, Sagent, 150 mg/mL, 60 mL bulk vial, 1 count, NDC 25021-0115-51
    • Clindamycin phosphate injection, Sandoz, 300 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00781-3288-09
    • Clindamycin phosphate injection, Sandoz, 600 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00781-3289-09
    • Clindamycin phosphate injection, Sandoz, 900 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00781-3290-09

Estimated Resupply Dates

    • Baxter has all clindamycin phosphate injection presentations on back order and the company estimates a release date of mid-May 2020.
    • Pfizer has Cleocin 150 mg/mL 2 mL, 4 mL, and 6 mL ADD-Vantage vials on back order and the company estimates a release date of February 2023. Clindamycin 150 mg/mL 2 mL and 4 mL vials are available in limited supply. The 150 mg/mL 6 mL vials are on back order and the company estimates a release date of May 2020.
    • Sagent has clindamycin phosphate 150 mg/mL 2 mL and 4 mL vials on back order and the company estimates a release date of June 2020. The 6 mL vials are on allocation.

Updated

Updated May 7, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 13, 2013 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide